Pathophysiology of antihypertensive therapy with diuretics

Hypertension Research

Volumn 29, Issue 9, 2006, Pages 645-653

  Fukuda, Michio ^a   Kimura, Genjiro ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Circadian rhythm; Combination therapy; Diuretic resistance; Diuretics; Pressure natriuresis

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; NEW DRUG; POTASSIUM SPARING DIURETIC AGENT; SODIUM; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALGORITHM; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; BODY FLUID; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CIRCADIAN RHYTHM; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIURETIC THERAPY; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; DRUG POTENTIATION; ESSENTIAL HYPERTENSION; GLUCOSE INTOLERANCE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; LOW DRUG DOSE; METABOLIC DISORDER; NATRIURESIS; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM INTAKE; SODIUM METABOLISM; SUDDEN DEATH;

EID: 33750221711     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.29.645     Document Type: Review

References (77)

1. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002; 288: 2998-3007.
2. Psaty BM, Lumley T, Furberg CD, et al: Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289: 2534-2544.
3. Chobanian AV, Bakris GL, Black HR, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
4. Chobanian AV, Bakris GL, Black HR, et al: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
5. Kimura G, Brenner BM: The renal basis for salt sensitivity in hypertension, in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis and Management. New York, Raven Press, 1995, pp 1569-1588.
6. Saito F, Kimura G: Antihypertensive mechanism of diuretics based on pressure-natriuresis relationship. Hypertension 1996; 27: 914-918.
7. Kimura G, Uzu T, Nakamura S, Inenaga T, Fujii T: High sodium sensitivity and glomerular hypertension/hyperfiltration in primary aldosteronism. J Hypertens 1996; 14: 1463-1468.
8. Akita S, Sacks FM, Svetkey LP, Conlin PR, Kimura G: Effects of the Dietary Approaches to Stop Hypertension (DASH) diet on the pressure-natriuresis relationship. Hypertension 2003; 42: 8-13.
9. Zhou X, Matavelli LC, Ono H, Frohlich ED: Superiority of combination of thiazide with angiotensin-converting enzyme inhibitor or AT1-receptor blocker over thiazide alone on renoprotection in L-NAME/SHR. Am J Physiol Renal Physiol 2005; 289: F871-F879.
10. Brown MJ, Palmer CR, Castaigne A, et al: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-372.
11. de Leeuw PW, Ruilope LM, Palmer CR, et al: Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. Arch Intern Med 2004; 164: 2459-2464.
12. Fukuda M, Kimura G: Can calcium channel blockers preserve renal function better than diuretics during antihypertensive treatment? Arch Intern Med 2005; 165: 1312.
13. Marre M, Puig JG, Kokot F, et al: Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens 2004; 22: 1613-1622.
14. Uzu T, Harada T, Namba T, et al: Thiazide diuretics enhance nocturnal blood pressure fall and reduce proteinuria in immunoglobulin A nephropathy treated with angiotensin II modulators. J Hypertens 2005; 23: 861-865.
15. Guyton AC: Arterial Pressure and Hypertension, Circulatory Physiology III. Philadelphia, WB Saunders, 1980.
16. Guyton AC: Renal function curve - a key to understanding the pathogenesis of hypertension. Hypertension 1987; 10: 1-6.
17. Guyton AC: Dominant role of the kidneys and accessory role of whole-body autoregulation in the pathogenesis of hypertension. Am J Hypertens 1989; 2: 575-585.
18. Appel LJ, Moore TJ, Obarzanek E, et al, DASH Collaborative Research Group: A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997; 336: 1117-1124.
19. Sacks FM, Svetkey LP, Vollmer WM, et al: Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. N Engl J Med 2001; 344: 3-10.
20. Vollmer WM, Sacks FM, Ard J, et al: Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. Ann Intern Med 2001; 135: 1019-1028.
21. Kimura G, Brenner BM: Implications of linear pressure-natriuresis relationship and importance of sodium sensitivity in hypertension. J Hypertens 1997; 15: 1055-1061.
22. Kimura G, Saito F, Kojima S, et al: Renal function curve in patients with secondary forms of hypertension. Hypertension 1987; 10: 11-15.
23. Parfrey PS: Salt in essential hypertension, in Sleight P, Freis ED (eds): Hypertension. Butterworth's International Medical Reviews, Cardiology 1. London, Butterworth, 1982, pp 322-339.
24. Parfrey PS, Markandu ND, Roulstone JE, Jones BE, Johnes JC, MacGregor GA: Relation between arterial pressure, dietary sodium intake and renin system in essential hypertension. Br Med J 1981; 283: 94-97.
25. Kimura G, Deguchi F, Kojima S, et al: Antihypertensive drugs and sodium restriction. Analysis of their interaction based on pressure-natriuresis relationship. Am J Hypertens 1988; 1: 372-379.
26. Kimura G, Abe H, Ashida T, et al: Hypotensive mechanisms of antihypertensives based on the water tank model. Am J Hypertens 1989; 2: 532-536.
27. Materson BJ, Reda DJ, Cushman WC, et al, The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents: Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328: 914-921.
28. Deary AJ, Schumann AL, Murfet H, Haydock SF, Foo RS, Brown MJ: Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. J Hypertens 2002; 20: 771-777.
29. Morgan T, Lauri J, Bertram D, Anderson A: Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004; 17: 118-123.
30. SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3264.
31. MacMahon S, Rodgers A: The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertensives. Clin Exp Hypertens 1993; 15: 967-978.
32. Hebert PR, Moser M, Mayer J, Glynn RJ, Hennekens CH: Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993; 153: 578-581.
33. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
34. Williams B, Poulter NR, Brown MJ, et al: Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004 - BHS IV. J Hum Hypertens 2004; 18: 139-185.
35. Japanese Society of Hypertension Guidelines Subcommittee for the Management of Hypertension: Guidelines for the management of hypertension for general practitioners. Hypertens Res 2001; 24: 613-634.
36. Uzu T, Kimura G: Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation 1999; 100: 1635-1638.
37. Uzu T, Kazembe FS, Ishikawa K, Nakamura S, Inenaga T, Kimura G: High sodium sensitivity implicates nocturnal hypertension in essential hypertension. Hypertension 1996; 28: 139-142.
38. Uzu T, Ishikawa K, Fujii T, Nakamura S, Inenaga T, Kimura G: Sodium restriction shifts circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation 1997; 96: 1859-1862.
39. Fujii T, Uzu T, Nishimura M, et al: Circadian rhythm of natriuresis is disturbed in non-dipper type of essential hypertension. Am J Kidney Dis 1999; 33: 29-35.
40. Uzu T, Nishimura M, Fujii T, et al: Changes in the circadian rhythm of blood pressure in primary aldosteronism in response to dietary sodium restriction and adrenalectomy. J Hypertens 1998; 16: 1745-1748.
41. Harshfield GA, Alpert BS, Willey ES, Somes GW, Murphy JK, Dupaul LM: Race and gender influence ambulatory blood pressure patterns of adolescents. Hypertension 1989; 14: 598-603.
42. Agyemang C, Bhopal R, Bruijnzeels M, Redekop WK: Does nocturnal blood pressure fall in people of African and South Asian descent differ from that in European white populations? A systematic review and meta-analysis. J Hypertens 200; 23: 913-920.
43. Fukuda M, Munemura M, Usami T, et al: Nocturnal blood pressure is elevated with natriuresis and proteinuria as renal function deteriorates in nephropathy. Kidney Int 2004; 65: 621-625.
44. Kimura G: Sodium, kidney, and circadian rhythm of blood pressure. Clin Exp Nephrol 2001; 5: 13-18.
45. O'Brien E, Sheridan J, O'Malley K: Dippers and non-dippers. Lancet 1988; 2: 397.
46. Verdecchia P, Schillaci G, Guerrieri M, et al: Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 1990; 81: 528-536.
47. Shimada K, Kawamoto A, Matsubayashi K, Ozawa T: Silent cerebrovascular disease in the elderly. Correlation with ambulatory pressure. Hypertension 1990; 16: 692-699.
48. Verdecchia P, Porcellati C, Schillaci G, et al: Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 1994; 24: 793-801.
49. Pickering TG: The clinical significance of diurnal blood pressure variations. Dippers and nondippers. Circulation 1990; 81: 700-702.
50. Staessen JA, Thijs L, Fagard R, et al, Systolic Hypertension in Europe Trial Investigators: Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA 1999; 282: 539-546.
51. Mancia G, Facchetti R, Bombelli M, et al: Relationship of office, home, and ambulatory blood pressure to blood glucose and lipid variables in the PAMELA population. Hypertension 2005; 45: 1072-1077.
52. Dolan B, Stanton A, Thijs L, et al: Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 2005; 46: 156-161.
53. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629-636.
54. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (2 Suppl 1): S1-S266.
55. Sarnak MJ, Levey AS, Schoolwerth AC, et al: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-2169.
56. Ritz E, McClellan WM: Overview: increased cardiovascular risk in patients with minor renal dysfunction: an emerging issue with far-reaching consequences. J Am Soc Nephrol 2004; 15: 513-516.
57. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
58. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR: Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-232.
59. Goto N, Uchida K, Morozumi K, et al: Circadian blood pressure rhythm is disturbed by nephrectomy. Hypertens Res 2005; 28: 301-306.
60. Kimura G: Glomerular function reserve and sodium sensitivity. Clin Exp Nephrol 2005; 9: 102-113.
61. Morimoto A, Uzu T, Fujii T, et al: Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet 1997; 350: 1734-1737.
62. Kimura G: Sodium sensitivity of blood pressure: a new prognostic factor in hypertension. Nephron 1999; 83: 97-105.
63. Weinberger MH, Fineberg NS, Fineberg SE, Weinberger M: Salt sensitivity, pulse pressure, and death in normal and hypertensive humans. Hypertension 2001; 37 (2 Part 2): 429-432.
64. Law MR, Wald NJ, Morris JK, Jordan RE: Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326: 1427.
65. Siscovick DS, Raghunathan TE, Psaty BM, et al: Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994; 330: 1852-1857.
66. Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB: Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension 2000; 35: 1025-1030.
67. Verdecchia P, Reboldi G, Angeli F, et al: Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43: 963-969.
68. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR: Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005; 95: 29-35.
69. Inaba M, Noguchi Y, Yamamoto T, et al: Effects of a low dose of indapamide, a diuretic, given daily or every-other-day on blood pressure and metabolic parameters. Hypertens Res 2004; 27: 141-145.
70. Doulton TW, He FJ, MacGregor GA: Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 2005; 45: 880-886.
71. Dahlof B, Devereux RB, Kjeldsen SE, et al: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
72. Lindholm LH, Ibsen H, Dahlof B, et al: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004-1010.
73. Dahlof B, Devereux RB, Kjeldsen SE: Diuretics in the LIFE study. Lancet 2004; 364: 413-414.
74. Dahlof B, Sever PS, Poulter NR, et al: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
75. Poulter NR, Wedel H, Dahlof B, et al: Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366: 907-913.
76. Epstein M, Messerli FM: Combination therapy in the management of hypertension, in Messerli FM (ed): The ABCs of Antihypertensive Therapy. New York, Authors' Publishing House, 2000; pp 204-221.
77. Kaplan NM: Clinical Hypertension. Philadelphia, Lippincott, 2002.